Cargando…

Recurrent Metastasized Parathyroid Carcinoma—Long‐Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide

Parathyroid carcinoma is a rare cause of primary hyperparathyroidism with rather poor prognosis. Apart from surgery, no evidence‐based treatments exist. A 48‐year‐old woman presented with weight loss, nausea, constipation, hypercalcemic crisis, and a recurrent neck tumor 5 years after primary surger...

Descripción completa

Detalles Bibliográficos
Autores principales:	Storvall, Sara, Ryhänen, Eeva, Bensch, Frank V, Heiskanen, Ilkka, Kytölä, Soili, Ebeling, Tapani, Mäkelä, Siru, Schalin‐Jäntti, Camilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478586/ https://www.ncbi.nlm.nih.gov/pubmed/31044184 http://dx.doi.org/10.1002/jbm4.10114

Ejemplares similares

MGMT Promoter Methylation and Parathyroid Carcinoma
por: Storvall, Sara, et al.
Publicado: (2019)

Novel PRUNE2 Germline Mutations in Aggressive and Benign Parathyroid Neoplasms
por: Storvall, Sara, et al.
Publicado: (2023)

Somatostatin receptor expression in parathyroid neoplasms
por: Storvall, Sara, et al.
Publicado: (2019)

Health-related quality of life is impaired in primary hyperparathyroidism and significantly improves after surgery: a prospective study using the 15D instrument
por: Ryhänen, Eeva M, et al.
Publicado: (2015)

CDC73 Intragenic Deletion in Familial Primary Hyperparathyroidism Associated With Parathyroid Carcinoma
por: Korpi-Hyövälti, Eeva, et al.
Publicado: (2014)

(99m)Technetium Sestamibi-(123)Iodine Scintigraphy Is More Accurate Than (99m)Technetium Sestamibi Alone before Surgery for Primary Hyperparathyroidism
por: Ryhänen, Eeva M., et al.
Publicado: (2015)

Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report
por: Ryhänen, Eeva M., et al.
Publicado: (2021)

Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1
por: Yliaska, Iina, et al.
Publicado: (2022)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Cushing's syndrome, pheochromocytoma, or both?
por: Kullamaa, Liisa, et al.
Publicado: (2023)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss‐of‐Function Gα(11) Mutation
por: Gorvin, Caroline M, et al.
Publicado: (2017)

IDH1 Expression via the R132H Mutation–Specific Antibody in Adrenocortical Neoplasias—Prognostic Impact in Carcinomas
por: Pennanen, Mirkka, et al.
Publicado: (2020)

Clonal dynamics using droplet digital polymerase chain reaction in peripheral blood predicts treatment responses in myelodysplastic syndrome
por: Illman, Johanna, et al.
Publicado: (2022)

The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma
por: Nadarasa, K, et al.
Publicado: (2014)

Adrenocortical carcinoma: presentation and outcome of a contemporary patient series
por: Kostiainen, Iiro, et al.
Publicado: (2019)

Successful use of cinacalcet to treat parathyroid-related hypercalcemia in two pediatric patients
por: Mogas, E, et al.
Publicado: (2018)

Case report of a cystic parathyroidal adenoma with rapid growth induced by cinacalcet
por: Werner, Christoph, et al.
Publicado: (2020)

SAT-349 Cinacalcet Resistant Tertiary Hyperparathyroidism with One Large Parathyroid Gland
por: Chaker, Bayan, et al.
Publicado: (2020)

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy
por: Koda, Ryo, et al.
Publicado: (2014)

Adrenal androgens versus cortisol for primary aldosteronism subtype determination in adrenal venous sampling
por: Viukari, Marianna, et al.
Publicado: (2022)

Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas
por: Sugi, Orie, et al.
Publicado: (2010)

Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone
por: Shahen, V. A., et al.
Publicado: (2023)

Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT)
por: Bollerslev, Jens, et al.
Publicado: (2019)

Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD
por: Miller, Gerald, et al.
Publicado: (2012)

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
por: Meola, Mario, et al.
Publicado: (2009)

Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
por: Bech, Anneke, et al.
Publicado: (2012)

Association Between Resistance to Cinacalcet and Parathyroid Gland Hyperplasia in Kidney Transplant Recipients with Persistent Hypercalcemia
por: Oruc, A., et al.
Publicado: (2020)

European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021)
por: Bollerslev, Jens, et al.
Publicado: (2021)

Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms
por: Becker, Anna, et al.
Publicado: (2021)

Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients
por: Kim, Jwa-Kyung, et al.
Publicado: (2013)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report
por: Takada, Daisuke, et al.
Publicado: (2017)

Cinacalcet is effective in the treatment of hyperparathyroidism secondary to malignant transformation of autotransplanted parathyroid tissue. A case report
por: Dattolo, Pietro, et al.
Publicado: (2010)

Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy
por: Bolasco, Piergiorgio, et al.
Publicado: (2010)

The Effect of the Frequently Used Cinacalcet for pHPT during the COVID-19 Pandemic on Perioperative Decrease in Parathyroid Hormone
por: Radulova-Mauersberger, Olga, et al.
Publicado: (2022)

The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?
por: Date, Toshiyuki, et al.
Publicado: (2008)

A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion
por: Schalin-Jäntti, Camilla, et al.
Publicado: (2015)

Cinacalcet: the chemical parathyroidectomy?
por: Bellasi, Antonio, et al.
Publicado: (2013)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m7db6lu497h7leif4r414refg2